Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

NCT00607971 is registered in ClinicalTrials.gov with Alizyme as lead sponsor.

NCT NCT00607971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00607971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Open Label, Extension Study to Evaluate the Long-Term Safety of Renzapride 4 mg Once Daily in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
Lead sponsor
Alizyme
Phase
Phase 3
Overall status
Terminated
Start date
April 30, 2006
Completion date
June 30, 2008
Enrollment
939 (actual)
Sites
126

Conditions

As the registry lists them; a condition with its own page is linked.

constipation-predominant irritable bowel syndrome